Patents for A61P 35 - Antineoplastic agents (221,099)
03/2006
03/15/2006EP1633769A1 Novel transcription factor, bp1
03/15/2006EP1633751A1 Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
03/15/2006EP1633749A2 Deazaflavin compounds and methods of use thereof
03/15/2006EP1633738A2 Novel indole derivatives, method of preparing same in the form of medicaments, pharmaceutical compositions and, in particular, kdr inhibitors
03/15/2006EP1633735A1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
03/15/2006EP1633718A2 COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
03/15/2006EP1633713A1 Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3
03/15/2006EP1633712A2 Six membered amino-amide derivatives as angiogenesis inhibitors
03/15/2006EP1633710A1 Isoindolin-1-one compounds as kinase inhibitors
03/15/2006EP1633396A1 Cd20 binding molecules
03/15/2006EP1633394A1 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
03/15/2006EP1633380A2 Antimicrobial and anticancer lipopeptides
03/15/2006EP1633365A1 Macrocyclic quinazoline derivatives as antiproliferative agents
03/15/2006EP1633352A1 Polyene oxazoles with antitumour activity and processes for their preparation using a streptomyces strain
03/15/2006EP1633346A1 Pyrrolidin-1, 2- dicarboxylic acid- 1- (4- ethinyl- phenyl) - amid]- 2- (phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis
03/15/2006EP1633342A2 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
03/15/2006EP1633341A2 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
03/15/2006EP1633316A2 Antibodies that immunospecifically bind to trail receptors
03/15/2006EP1633309A2 Method of inhibiting tumor growth with anti-tissue factor antibodies
03/15/2006EP1513834B1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same
03/15/2006EP1470155B1 Pluripotency determining factor and uses thereof
03/15/2006EP1465864B1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
03/15/2006EP1435908A4 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
03/15/2006EP1417300B1 Process for the maturation of dentritic cells and a vaccine
03/15/2006EP1408962B1 Substituted isoindoles and the use thereof
03/15/2006EP1372648B1 Tie2 receptor kinase inhibitors for treating angiogenic diseases
03/15/2006EP1331937B1 Dibenzoxazepine alpha v integrin receptor antagonist
03/15/2006EP1326864B1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
03/15/2006EP1309589B1 Urea compounds and methods of uses
03/15/2006EP1289992B1 New crystalline form of a triazolo(4,5-d)pyrimidine compound
03/15/2006EP1227085B1 Process for producing optically active naphthalene derivative and optical resolver therefor
03/15/2006EP1044022B1 Compositions and methods for targeted delivery of factors
03/15/2006EP0934292B1 Metalloproteinase inhibitors
03/15/2006EP0929554B1 Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
03/15/2006EP0892849B1 Methods for using the obese gene and its gene product to stimulate hematopoietic development
03/15/2006EP0784477B1 Immunotherapeutic stress protein-peptide complexes against cancer
03/15/2006CN1748029A Oligomeric compounds for the modulation of survivin expression
03/15/2006CN1747984A Polymer guanidine derivatives as a cytostatic medicament
03/15/2006CN1747964A Medicament for inhibiting tumour growth
03/15/2006CN1747953A Aryl / hetaryl substituted imidazoquinolines.
03/15/2006CN1747952A Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
03/15/2006CN1747950A 2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
03/15/2006CN1747948A Novel n-monoacylated o-phenylenediamines, their condensed heterocyclic derivatives and their use as pharmaceutical agents
03/15/2006CN1746190A Modified peptides as therapeutic agents
03/15/2006CN1746189A Modified peptides as therapeutic agents
03/15/2006CN1746184A Trichosanthin mutant and coding gene thereof
03/15/2006CN1746164A Protein antagonist with water channel
03/15/2006CN1745845A Chinese medicinal composition for treating and inhibiting tumor, its preparation and use
03/15/2006CN1745843A Anticancer Chinese medicine compound preparation and its making method thereof
03/15/2006CN1745782A Taxol fruit infusion granule
03/15/2006CN1745759A External-applied medicine for inhibitting and killing cancer and tumor cells
03/15/2006CN1745758A Compound taxol Chinese medicinal preparation
03/15/2006CN1745749A Likejun capsule and production thereof
03/15/2006CN1245407C Composition of garcinolic acid compounds, its preparing process and medical composition using it as active component
03/15/2006CN1245402C Indole derivatives, their preparation, medicinal compositions containing them and use thereof
03/15/2006CN1245388C Process for synthesis of lonidamine
03/15/2006CN1245385C Indole and dihydroindole derivatives
03/15/2006CN1245382C 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
03/15/2006CN1245381C Phenylglycine derivatives
03/15/2006CN1245216C Stabilized liquid polypeptide-containing. pharmaceutical compositions
03/15/2006CN1245215C Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor
03/15/2006CN1245213C Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method
03/15/2006CN1245207C Modified technique for making zedoary turmeric oil and glucose injection
03/15/2006CN1245205C Chinese medicine for treating alimentary system malignant tumour
03/15/2006CN1245167C Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
03/15/2006CA2480231A1 Rapid insufflation drug compartment
03/14/2006US7012146 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
03/14/2006US7012133 Antibodies to C-C chemokine Receptor 3 Protein
03/14/2006US7012098 Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
03/14/2006US7012095 Compounds for modulating cell proliferation
03/14/2006US7012089 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist
03/14/2006US7012087 Anticancer agents
03/14/2006US7012081 Antiproliferative agents; skin disorders; vision defects; liver and kidney disorders
03/14/2006US7012079 (5R)-5-ethyl-9,10,difluoro-5-hydroxy-12-(2-trimethylsilylethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]-indoloizino[1,2-b]quinoline-3,15-dione for treatment of colon cancer
03/14/2006US7012077 Anticholesterol agents; antilipemic agents
03/14/2006US7012076 Quinazoline-4-sulfonamide derivatives
03/14/2006US7012075 Cathepsin cysteine protease inhibitors
03/14/2006US7012068 Reduced toxicity; enhance efficiency; side effect reduction
03/14/2006US7011973 recombinant DNA molecules comprising regulatory sequences of an intron of the Vascular Endothelial Growth Factor receptor-2 gene or of a gene homologous to the Flk-1 gene, being capable of conferring expression of a heterologous DNA sequence
03/14/2006US7011851 Drug delivery; incontinence therapy
03/14/2006US7011845 For therapy and prophylaxis of infection or tumor
03/14/2006CA2584412A1 Methods for diagnosis and treatment of cancer
03/14/2006CA2359363C 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
03/14/2006CA2312935C Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
03/14/2006CA2278241C Phenyl heterocycles as cyclooxygenase-2 inhibitors
03/14/2006CA2268796C Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
03/14/2006CA2267879C Heteroaryl succinamides and their use as metalloproteinase inhibitors
03/14/2006CA2250731C In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
03/14/2006CA2214070C Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
03/14/2006CA2147984C Butenyl-substituted taxanes and composition
03/09/2006WO2006026656A1 Cytotoxic nucleoside analog compound 003 for treating cancer
03/09/2006WO2006026500A1 New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
03/09/2006WO2006026348A1 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
03/09/2006WO2006025567A1 Novel substituted imidazole derivatives
03/09/2006WO2006025490A1 Molecular chaperone function regulator
03/09/2006WO2006025431A1 Antagonist against tolerance to anticancer drugs
03/09/2006WO2006025411A1 Liposome improving intracellular drug delivery
03/09/2006WO2006025286A1 Constitutional function-improving agents
03/09/2006WO2006025251A1 Physiologically active substances biselide a, biselide b, and biselide c, processes for producing these, and uses of these
03/09/2006WO2006024863A1 Stable crystal form of imatinib mesylate and process for the preparation thereof